Companion Diagnostics for Oncology Market Size, Share and Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Companion Diagnostics for Oncology Market Size Analysis

Global Companion Diagnostics for Oncology Market Introduction
By Products and Services
1. Introduction
  1. Products and Services By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Software and Services
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-Generation Sequencing (NGS)
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Gastric Cancer
  1. By Value
6. Melanoma
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Laboratories
  1. By Value
4. Contract Research Organizations
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Products and Services
1. Introduction
  1. Products and Services By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Software and Services
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-Generation Sequencing (NGS)
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Gastric Cancer
  1. By Value
6. Melanoma
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Laboratories
  1. By Value
4. Contract Research Organizations
  1. By Value
5. Others
  1. By Value
U.S.
1. By Products and Services
  1. Introduction
    1. Products and Services By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Software and Services
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-Generation Sequencing (NGS)
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Gastric Cancer
    1. By Value
  6. Melanoma
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Laboratories
    1. By Value
  4. Contract Research Organizations
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Products and Services
1. Introduction
  1. Products and Services By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Software and Services
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-Generation Sequencing (NGS)
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Gastric Cancer
  1. By Value
6. Melanoma
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Laboratories
  1. By Value
4. Contract Research Organizations
  1. By Value
5. Others
  1. By Value
U.K.
1. By Products and Services
  1. Introduction
    1. Products and Services By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Software and Services
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-Generation Sequencing (NGS)
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Gastric Cancer
    1. By Value
  6. Melanoma
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Laboratories
    1. By Value
  4. Contract Research Organizations
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Products and Services
1. Introduction
  1. Products and Services By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Software and Services
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-Generation Sequencing (NGS)
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Gastric Cancer
  1. By Value
6. Melanoma
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Laboratories
  1. By Value
4. Contract Research Organizations
  1. By Value
5. Others
  1. By Value
China
1. By Products and Services
  1. Introduction
    1. Products and Services By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Software and Services
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-Generation Sequencing (NGS)
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Gastric Cancer
    1. By Value
  6. Melanoma
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Laboratories
    1. By Value
  4. Contract Research Organizations
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Products and Services
1. Introduction
  1. Products and Services By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Software and Services
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-Generation Sequencing (NGS)
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Gastric Cancer
  1. By Value
6. Melanoma
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Laboratories
  1. By Value
4. Contract Research Organizations
  1. By Value
5. Others
  1. By Value
UAE
1. By Products and Services
  1. Introduction
    1. Products and Services By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Software and Services
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-Generation Sequencing (NGS)
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Gastric Cancer
    1. By Value
  6. Melanoma
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Laboratories
    1. By Value
  4. Contract Research Organizations
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Products and Services
1. Introduction
  1. Products and Services By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Software and Services
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-Generation Sequencing (NGS)
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Gastric Cancer
  1. By Value
6. Melanoma
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Laboratories
  1. By Value
4. Contract Research Organizations
  1. By Value
5. Others
  1. By Value
Brazil
1. By Products and Services
  1. Introduction
    1. Products and Services By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Software and Services
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-Generation Sequencing (NGS)
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Gastric Cancer
    1. By Value
  6. Melanoma
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Laboratories
    1. By Value
  4. Contract Research Organizations
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Companion Diagnostics for Oncology Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Qiagen N.V.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
F. Hoffmann La Roche Ltd
Agilent Technologies
Thermo Fisher Scientific
Abbott
Amoy diagnostics
BioMérieux SA
Archerdx
Illumina, Inc.
Foundation Medicine, Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment